<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022359</url>
  </required_header>
  <id_info>
    <org_study_id>08/H0710/24</org_study_id>
    <nct_id>NCT01022359</nct_id>
  </id_info>
  <brief_title>Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters</brief_title>
  <acronym>VyTes</acronym>
  <official_title>Comparison of Tesio and LifeCath Twin Permanent Dialysis Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College Healthcare NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare two available types of central venous haemodialysis catheters&#xD;
      (lines) - CVCs, and will examine how easy they are to insert, complications, blood flow on&#xD;
      dialysis over time, line loss, line clotting and infective events. It will examine whether&#xD;
      the LifeCath type of CVC can deliver high blood flow rates from first use after insertion and&#xD;
      equivalent function and complication rate to the Tesio type of CVC that is in use in our&#xD;
      centre already. Complications relating to dialysis access make up 30% of admissions for&#xD;
      haemodialysis patients and so this is a study that could benefit patients and their care&#xD;
      providers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Complications relating to dialysis access make up to 30% of admissions in haemodialysis&#xD;
      patients. Comparative studies of complications between dialysis lines can help physicians and&#xD;
      patients choose the best CVC type. In addition determining a type of dialysis line that can&#xD;
      deliver good blood flows from the outset can minimise length of hospital stay for access&#xD;
      creation. This study aims to perform a head-to-head comparison of two very similar (twin&#xD;
      catheter) dialysis lines and examine short and long-term function as well as complication&#xD;
      rates at our centre.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Flow Rate at First Use After Insertion</measure>
    <time_frame>First haemodialysis session after insertion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of Flow Rates&gt;=450ml/Min at Dialysis Session</measure>
    <time_frame>flow rate measured at each session; session at 12 months reported</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Line Retention (Either/Both Lumens)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infective Episodes (Catheter &amp; Non-catheter Related)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter Dysfunction Requiring Use of Thrombolytic Agents</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications at Catheter Insertion</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recirculation Rates</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Tesio Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to receive the established catheter type in use at our centre [control]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LifeCath</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TesioCath</intervention_name>
    <description>Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
    <arm_group_label>Tesio Catheter</arm_group_label>
    <other_name>BioFlex TesioCath (TM) - MedComp, Harleysville, PA, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LifeCath Twin</intervention_name>
    <description>Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
    <arm_group_label>LifeCath</arm_group_label>
    <other_name>Vygon LifeCath Twin - Vygon(UK) Ltd, Cirencester, Gloucs, UK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=18 years old&#xD;
&#xD;
          -  No history of prior central venous catheter insertion&#xD;
&#xD;
          -  Medically fit for procedure (able to lie flat, no haemodynamic instability)&#xD;
&#xD;
          -  No active infection (recent positive blood cultures, clinical signs of infection,&#xD;
             CRP&gt;100)&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Expected to survive more than 12 months after catheter insertion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neill Duncan, MBBS MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Power, MBBChir MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Duncan ND, Singh S, Cairns TD, Clark M, El-Tayar A, Griffith M, Hakim N, Hamady M, McLean AG, Papalois V, Palmer A, Taube D. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant. 2004 Nov;19(11):2816-22. Epub 2004 Aug 31.</citation>
    <PMID>15340094</PMID>
  </reference>
  <reference>
    <citation>Perini S, LaBerge JM, Pearl JM, Santiestiban HL, Ives HE, Omachi RS, Graber M, Wilson MW, Marder SR, Don BR, Kerlan RK Jr, Gordon RL. Tesio catheter: radiologically guided placement, mechanical performance, and adequacy of delivered dialysis. Radiology. 2000 Apr;215(1):129-37.</citation>
    <PMID>10751478</PMID>
  </reference>
  <reference>
    <citation>Hassell DD 3rd, Vesely TM, Pilgram TK, Audrain JL. Initial performance of Tesio hemodialysis catheters. J Vasc Interv Radiol. 1999 May;10(5):553-8.</citation>
    <PMID>10357479</PMID>
  </reference>
  <results_reference>
    <citation>Power A, Hill P, Singh SK, Ashby D, Taube D, Duncan N. Comparison of Tesio and LifeCath twin permanent hemodialysis catheters: the VyTes randomized trial. J Vasc Access. 2014 Mar-Apr;15(2):108-15. doi: 10.5301/jva.5000202. Epub 2014 Feb 5.</citation>
    <PMID>24500851</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <results_first_submitted>March 2, 2021</results_first_submitted>
  <results_first_submitted_qc>March 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2021</results_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>haemodialysis</keyword>
  <keyword>vascular access</keyword>
  <keyword>central venous catheter</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tesio Catheter</title>
          <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
        </group>
        <group group_id="P2">
          <title>LifeCath</title>
          <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tesio Catheter</title>
          <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
        </group>
        <group group_id="B2">
          <title>LifeCath</title>
          <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.3" spread="15.6"/>
                    <measurement group_id="B2" value="58.9" spread="16.4"/>
                    <measurement group_id="B3" value="61" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="41"/>
                    <count group_id="B3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Flow Rate at First Use After Insertion</title>
        <time_frame>First haemodialysis session after insertion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Flow Rate at First Use After Insertion</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="79"/>
                    <measurement group_id="O2" value="383" spread="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of Flow Rates&gt;=450ml/Min at Dialysis Session</title>
        <time_frame>flow rate measured at each session; session at 12 months reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Flow Rates&gt;=450ml/Min at Dialysis Session</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361" spread="48"/>
                    <measurement group_id="O2" value="379" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Line Retention (Either/Both Lumens)</title>
        <time_frame>12 months</time_frame>
        <population>measure not taken</population>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Line Retention (Either/Both Lumens)</title>
          <population>measure not taken</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infective Episodes (Catheter &amp; Non-catheter Related)</title>
        <time_frame>12 months</time_frame>
        <population>measure not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Infective Episodes (Catheter &amp; Non-catheter Related)</title>
          <population>measure not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Catheter Dysfunction Requiring Use of Thrombolytic Agents</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Catheter Dysfunction Requiring Use of Thrombolytic Agents</title>
          <units>thrombolytic infusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications at Catheter Insertion</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Complications at Catheter Insertion</title>
          <units>complications at insertion</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recirculation Rates</title>
        <time_frame>12 months</time_frame>
        <population>measure not taken</population>
        <group_list>
          <group group_id="O1">
            <title>Tesio Catheter</title>
            <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
          </group>
          <group group_id="O2">
            <title>LifeCath</title>
            <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
          </group>
        </group_list>
        <measure>
          <title>Recirculation Rates</title>
          <population>measure not taken</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of trial, 12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tesio Catheter</title>
          <description>Patients randomised to receive the established catheter type in use at our centre [control]&#xD;
TesioCath: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access</description>
        </group>
        <group group_id="E2">
          <title>LifeCath</title>
          <description>Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)&#xD;
LifeCath Twin: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>severe hemorrhagic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>metastatic malignancy that was diagnosed 9 months following CVC insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neill Duncan</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0 )207 594 7243</phone>
      <email>n.duncan@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

